• Accueil
• mcv4
• CanSinoBIO announces approval for its MCV4 meningococcal vaccine Menhycia in China

CanSinoBIO announces approval for its MCV4 meningococcal vaccine Menhycia in China

4.9 (760) · € 18.99 · En Stock

China's CanSino in mRNA vaccine deal with AstraZeneca

China's CanSino seeks more vaccine contracts after AstraZenca deal

Articles about Tianjin CanSino Biologics

Clival Database

Student confirmed as third case of meningococcal disease in

Meningococcal immunizecanada

ARCHIVED Update on Quadrivalent Meningococcal Vaccines available

康希诺生物 CanSinoBIO

CanSinoBIO Rebrands to Reflect Commitment to Life Sciences Research

China's CanSino reports 'positive' interim data from COVID mRNA

China's CanSino in mRNA vaccine deal with AstraZeneca

Articles about Tianjin CanSino Biologics

康希诺生物 CanSinoBIO